Wuxi Pharmatech Usd 70 Million Ends Up Pocket
Shanghai Pudong Zhangjiang, in recent years, will bring together a large number of drug development
, production and management company, known as "China Valley", when the news broke. September 7, the reporter learned from the Shanghai municipal government concerned, in the "trough of China" in WuXi PharmaTech, leading Pharmaceutical, Genomics and other biomedical companies, in recent years to build first-class R & D and high-end services platform, actively undertake international pharmaceutical R & D outsourcing services, "gains a lot of money." Among them, only to WuXi PharmaTech's international pharmaceutical R & D outsourcing services customers include the world's top 10 biopharmaceutical companies in the eight, last year income of 70 million U.S. dollars to achieve the contract about the industry admiration.
"We are partners not only advanced scientific research facilities and equipment, along with the expansion of drug development and expansion of outsourcing services, WuXi PharmaTech will partner to provide more and better services, to become integrated R & D service firms in the world arena. "WuXi PharmaTech Ge Li, Chairman and CEO, says.
According to Wang, the world's great biomedical R & D outsourcing market, this market now, "cake" of about 20 billion U.S. dollars, is expected to increase to 300 by 2010 million. In this regard, the Shanghai Pudong District government agencies and organizations actively seek to mobilize the enterprise itself to cutting big enough piece of "cake." In early 2005, more than 30 R & D outsourcing company in Pudong, given the opportunity went to Philadelphia to attend there at the "Global Biotechnology Annual Meeting." For the first time to go abroad, "China Valley" more than 30 companies subject to immediate attention, the U.S. Eli Lilly, Wyeth, Merck and other large enterprises, and then have come as some field trips, and met with the "China Valley" within the Charles Shi Rui Hua, bio-chip companies such as R & D outsourcing agreement signed, with orders pouring in. overseas pharmaceutical R & D, anti-2004, the Pudong region's biomedical R & D outsourcing service company to complete the output value reached 220 million yuan; last year, that figure has increased to 7 billion.
"Harvest too! Site customers make an appointment, an average of 30 minutes a file is almost full time the whole negotiation." Shanghai Medicilon Limited (Shanghai U.S. Ducie company) CEO Chen Chunlin had just come back from the exhibition in Boston, he seemed especially excited. In the "trough of China" in Shanghai U.S. Ducie company, is a drug discovery research featured companies, corporate management team has many years by a group of overseas high-tech pharmaceutical and biotechnology companies, and management experience PhDs. Technological research and development mainly related to structural biology, drug design, pharmaceutical chemistry and pharmacy; main business is engaged in chemical and pharmaceutical pre-clinical studies. They used sophisticated protein crystallization, QSAR technology and high-throughput parallel synthesis of combinatorial chemistry, computer-aided drug design and combinatorial chemistry high throughput parallel synthesis, high throughput pharmacokinetics, drug metabolism, the formation of a certain ability to open up international markets , was optimistic about overseas partners.
5 years ago, "China Valley" is also only a few dozen biomedical companies??? Genomics, the last two years of its R & D outsourcing contract revenue nearly doubling every year, and fetched from the original 10 year million last year, soared to 200 million. It is understood, was established in August 2001 of Genomics by in America Boshi Luo Ying, Wu Chun and other returning students to featuring established, the first two companies jointly invested by Shanghai, after the investment by the GNI Ltd., a registered capital of 4300 million yuan.
It is understood, including Genomics, there are now in the "Chinese Medicine Valley," the rapid development of pharmaceutical R & D outsourcing company there are many, to the end of this year which will have four companies involved in biomedical R & D outsourcing overseas market, accounting for Shanghai city biomedical R & D outsourcing 10% of total number of enterprises. Of course, these pharmaceutical companies started from scratch to provide bigger R & D outsourcing services to overseas, it is self-accumulation, enhancing independent innovation capability of the main aspects. As a head of said pharmaceutical companies, in the initial stages of their first European and American pharmaceutical giants outsourcing R & D to do, not only in the short term of not less profit, more importantly, we seem to foreign pharmaceutical companies to "work", the actual take the forefront on the world of drug R & D "ride", not only to achieve the goal of intellectual capital accumulation, but also learned the management of international companies operating mode, people make up our own short length, so as to achieve the Chinese pharmaceutical companies extraordinary development "wings."
Wuxi Pharmatech Usd 70 Million Ends Up Pocket
By: mumu
Using Twittter To Maximize Your Results Target Ads Le but du savoir : Est-ce que le savoir humain a un but précis ? Office Desk - Efficiency Starts From Here driving fear Get A Perfect Tummy With Tummy Control Panties Southwest Flying High In International Skies Are you Ready to Get Rid of Pimples Fast? Diploma Mills - Fraud Institutions Big Plush Toy L'homme devant l'univers : Quoi-t-il pense ? Surprising Tricks For Decking Out Your Apartment For A Hollywood Atmosphere Handmade Soap Makes A Perfect Gift